Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Clinical trial NCT01339091 · COMPLETED

Trial details

NCT number: NCT01339091
Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Abscess Wound Infection Surgical Site Infection Cellulitis

Start date: 2011-03-01
Primary completion: 2012-09-01
Enrollment: 573

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.